Investors Archives - PharmaLive

Why Healthcare Companies Must Navigate Muddy Waters of ESG Requirements

Business, Corporate Responsibility, Gender diversity, Healthcare, Investors, Marketing & Advertising, Shareholders, Supply Chain, Sustainability

The need for more corporate responsibility has evolved for today’s corporations and the next generation of business leaders in the form of environmental, social and governance (ESG). Investors, activists, and regulators are now requiring proactive, community-structured commitment and accountability that is designed to step above shareholder returns. Today’s global capital markets aren’t interested in more marketing from companies in every industry. Instead, they are demanding sustainability and eco-friendly business practices as well as a reasonable return. Global healthcare companies and their executives are now hearing this call, and the industry is being more proactive in this movement.

May 2, 2022/by Andrew Humphreys

CytoDyn Hit with Two Clinical Holds

Brazil, Business, Clinical Hold, Clinical Trials, Coronavirus Disease 2019 (COVID-19), FDA, HIV, Investors, Partial Clinical Hold, R&D

The Food and Drug Administration placed a partial hold on CytoDyn’s HIV program and a full clinical hold on the company’s COVID-19 program in the United States.

March 31, 2022/by BioSpace

Cassava 10K Filing Warns of Anticipated Hold, Paints Dire Picture of Alzheimer’s Space

Cassava Sciences warned that the U.S. Food and Drug Administration might order a clinical hold on the company’s studies for the Alzheimer’s drug simufilam in 2022 after learning that two of its competitors received hold orders for similar research efforts.

March 3, 2022/by Andrew Humphreys

Biotech Stocks Take Hit as Wary Investors Look Elsewhere

Barron's, Biotech, Business, Coronavirus Disease (COVID-19) Pandemic, FDA/Regulatory, Financial Times, Financials, Investors, Nasdaq Biotech Index, Stocks

Over the past six months, the Nasdaq Biotechnology Index has declined more than 20%. Some of the falling prices appear to be due to some investors losing interest in many companies that soared into favor during the COVID-19 pandemic. And these companies that have seen declining investor interest are now struggling to raise finances, according to BioSpace

February 10, 2022/by BioSpace

Although the COVID-19 pandemic has hit companies unevenly, some biopharma firms that have produced new drugs or vaccines against the disease have shown big spikes in drug sales. BioSpace reviewed five companies that produced non-vaccine treatments for COVID-19.

February 8, 2022/by BioSpace

Pfizer’s COVID product sales to top $50 billion in 2022, investors want more

Antivirals, Business, Clinical Trials, Forecasts, Investors, Paxlovid, Pfizer, Quarterly results, R&D, Therapeutics

Pfizer Inc. expects 2022 sales of its COVID-19 vaccine and antiviral pill to top $54 billion, but that fell short of lofty Wall Street estimates and the biopharmaceutical company’s shares were off about 3 percent.

February 8, 2022/by Reuters Health

Bayer-Backed Biotech Snags $80 Million Series A for AI-Powered Cell Therapies

Artificial Intelligence, Bayer, Business, Cell Therapy, Financing, Investors, Series A

Cellino Biotech announced a completed Series A financing of $80 million led by the impact investment arm of Bayer AG, Leaps by Bayer, 8VC, and Humboldt Fund and includes new investor Felicis Ventures.

January 25, 2022/by BioSpace

Moderna asks investors to wait for full data on flu vaccine amid selloff

Business, Clinical Data, Clinical Trials, Flu Vaccines, Investors, Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), R&D

Moderna Inc. executives called on investors to wait for more data amid a sharp selloff in the company’s shares on Friday, after early data showed its mRNA-based flu vaccine was no better than already approved shots in the market.

December 10, 2021/by Reuters Health

Elizabeth Holmes denies misleading investors in trial testimony

Business, Elizabeth Holmes, Investors, Legal, Theranos, Trials

Theranos founder Elizabeth Holmes denied making misleading statements about the blood-testing startup during cross-examination on December 7, as her testimony in defense against fraud charges neared its end.

December 8, 2021/by Reuters Health

Cassava Reports Positive New Alzheimer’s Data

Alzheimer's, Business, Clinical Data, Clinical Trials, Cognitive Function, Investors, R&D, Topline Data

Cassava Sciences announced top-line results Sept. 22 from a 12-month interim analysis of the company’s Alzheimer’s drug candidate simufilam.

September 23, 2021/by Andrew Humphreys